newsfilter
← Latest News
PR Newswire·

Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial

  • First patient in the current dose cohort showed no cancer progression three months after treatment
  • Multiple patients have survived over one year, including one exceeding two years
  • No dose-limiting toxicities have been observed to date
  • The patient received the highest dose level evaluated (1×10⁷ CAR-positive cells/kg) in the fifth cohort
  • Stable disease was observed 90 days post-treatment, marking the first such response in the trial
  • The Phase 1 study evaluates safety, tolerability, & preliminary efficacy of liraltagene autoleucel (lira-cel) for recurrent ovarian cancer
  • The trial is conducted at Moffitt Cancer Center & targets the FSHR receptor expressed on ovarian cancer cells
  • Correlative studies on the presence & durability of CAR-positive cells remain ongoing